{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:51:42Z","timestamp":1788299502865,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Metformin is a commonly prescribed antidiabetic drug that inhibits hepatic glucose production (HGP). Recent studies examining the use of metformin for the treatment of children with metabolic dysfunction-associated steatotic liver disease (MASLD) showed controversial results. To evaluate the patient-specific impact of metformin on hepatic glucose, lipid, amino acid, and energy metabolism in a cohort of 70 paediatric patients with biopsy-proven MASH. We parametrized our mathematical model HEPATOKIN1 of liver metabolism with patient-specific proteomics data of liver enzyme abundances and simulated metformin-induced diurnal changes of a large panel of metabolic functions. On average, a single dose (250\u00a0mg) of metformin reduced diurnal HGP by 19%. Based on a Z-score of 1, 15% of patients were classified as low responders or high responders. During elevated metformin plasma levels within four after metformin ingestion, energy metabolism, cytosolic and mitochondrial redox potential, urea synthesis and ketone body synthesis were reduced by 10\u201330%, but averaged over 24\u00a0h, these metabolic side effects were not significant. In particular, there was no significant impact of metformin on hepatic fat storage. Baseline lactate and insulin activity at 90\u00a0min after glucose challenge (OGTT) correlated significantly with the reduction in HGP and may serve as predictors of effective therapy. On a daily average, metformin selectively affects hepatic glucose production, glycogen storage and lactate uptake, while numerous other metabolic functions are significantly altered only for several hours after administration of the drug. Our method provides a patient-specific analysis of the potential effects of metformin therapy on central hepatic metabolism and may therefore help guide the physician's therapeutic decision.<\/jats:p>","DOI":"10.1007\/s00109-025-02551-y","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:53:15Z","timestamp":1748361195000},"page":"837-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-specific effects of metformin on the hepatic metabolism in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-6023","authenticated-orcid":false,"given":"Hermann-Georg","family":"Holzh\u00fctter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Hudert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Berndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2551_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S0140-6736(18)31541-1","volume":"392","author":"SC Palmer","year":"2018","unstructured":"Palmer SC, Strippoli GF (2018) Metformin as first-line treatment for type 2 diabetes. The Lancet 392:120","journal-title":"The Lancet"},{"issue":"6","key":"2551_CR2","first-page":"56","volume":"2","author":"NP Johnson","year":"2014","unstructured":"Johnson NP (2014) Metformin use in women with polycystic ovary syndrome. Ann Transl Med 2(6):56","journal-title":"Ann Transl Med"},{"key":"2551_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s13679-019-00335-3","volume":"8","author":"A Yerevanian","year":"2019","unstructured":"Yerevanian A, Soukas AA (2019) Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep 8:156\u2013164","journal-title":"Curr Obes Rep"},{"key":"2551_CR4","first-page":"e2020086","volume":"91","author":"A Soliman","year":"2020","unstructured":"Soliman A, De Sanctis V, Alaaraj N, Hamed N (2020) The clinical application of metformin in children and adolescents: a short update. Acta Bio Medica: Atenei Parmensis 91:e2020086","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"key":"2551_CR5","first-page":"e2020086","volume":"91","author":"A Soliman","year":"2020","unstructured":"Soliman A, De Sanctis V, Alaaraj N, Hamed N (2020) The clinical application of metformin in children and adolescents: A short update. Acta Biomed 91:e2020086","journal-title":"Acta Biomed"},{"key":"2551_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3389\/fendo.2018.00753","volume":"9","author":"E Fontaine","year":"2018","unstructured":"Fontaine E (2018) Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences. Front Endocrinol 9:753","journal-title":"Front Endocrinol"},{"key":"2551_CR7","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1172\/JCI40671","volume":"120","author":"M Foretz","year":"2010","unstructured":"Foretz M, H\u00e9brard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state. J Clin Investig 120:2355\u20132369","journal-title":"J Clin Investig"},{"key":"2551_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"HR Bridges","year":"2014","unstructured":"Bridges HR, Jones AJ, Pollak MN, Hirst J (2014) Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462:475\u2013487","journal-title":"Biochem J"},{"key":"2551_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"TE LaMoia","year":"2021","unstructured":"LaMoia TE, Shulman GI (2021) Cellular and molecular mechanisms of metformin action. Endocr Rev 42:77\u201396","journal-title":"Endocr Rev"},{"key":"2551_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature13270","volume":"510","author":"AK Madiraju","year":"2014","unstructured":"Madiraju AK, Erion DM, Rahimi Y, Zhang X-M, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542\u2013546","journal-title":"Nature"},{"key":"2551_CR11","first-page":"CD002967","volume":"4","author":"SR Salpeter","year":"2010","unstructured":"Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD002967","journal-title":"Cochrane Database Syst Rev"},{"key":"2551_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.5009\/gnl20367","volume":"15","author":"K Pinyopornpanish","year":"2021","unstructured":"Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N (2021) Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut and liver 15:827","journal-title":"Gut and liver"},{"key":"2551_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12669\/pjms.35.1.100","volume":"35","author":"M Rashid","year":"2019","unstructured":"Rashid M, Shahzad M, Mahmood S, Khan K (2019) Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus. Pak J Med Sci 35:71","journal-title":"Pak J Med Sci"},{"key":"2551_CR14","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40618-022-01989-y","volume":"46","author":"M Vohra","year":"2023","unstructured":"Vohra M, Sharma A, Mallya S, Prabhu N, Jayaram P, Nagri S, Umakanth S, Rai P (2023) Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-na\u00efve type 2 diabetes. J Endocrinol Invest 46:1205\u20131218","journal-title":"J Endocrinol Invest"},{"key":"2551_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/jrsm.1202","volume":"7","author":"K Panayidou","year":"2016","unstructured":"Panayidou K, Gsteiger S, Egger M, Kilcher G, Carreras M, Efthimiou O, Debray TP, Trelle S, Hummel N, group, G. m. r. (2016) GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world. Res Synth Methods. 7:264\u2013277","journal-title":"Res Synth Methods."},{"key":"2551_CR16","doi-asserted-by":"publisher","first-page":"11072","DOI":"10.3390\/ijms231911072","volume":"23","author":"N Berndt","year":"2022","unstructured":"Berndt N, Hudert CA, Eckstein J, Loddenkemper C, Henning S, Bufler P, Meierhofer D, Sack I, Wiegand S, Wallach I (2022) Alterations of central liver metabolism of pediatric patients with non-alcoholic fatty liver disease. Int J Mol Sci 23:11072","journal-title":"Int J Mol Sci"},{"key":"2551_CR17","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/s41467-018-04720-9","volume":"9","author":"N Berndt","year":"2018","unstructured":"Berndt N, Bulik S, Wallach I, Wunsch T, Konig M, Stockmann M, Meierhofer D, Holzhutter HG (2018) HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology. Nat Commun 9:2386","journal-title":"Nat Commun"},{"key":"2551_CR18","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1111\/febs.14189","volume":"284","author":"C Wallstab","year":"2017","unstructured":"Wallstab C, Eleftheriadou D, Schulz T, Damm G, Seehofer D, Borlak J, Holzhutter HG, Berndt N (2017) A unifying mathematical model of lipid droplet metabolism reveals key molecular players in the development of hepatic steatosis. FEBS J 284:3245\u20133261","journal-title":"FEBS J"},{"key":"2551_CR19","first-page":"82","volume":"7","author":"W Mak","year":"2015","unstructured":"Mak W, Tan S, Wong J, Chin S, Looi I, Yuen K (2015) Bioequivalence study of two IR metformin formulations: an open-label, randomised, two treatments, two-way crossover study in healthy volunteers. J Bioequivalence Bioavailab 7:82","journal-title":"J Bioequivalence Bioavailab"},{"key":"2551_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11684-015-0384-0","volume":"9","author":"J Zheng","year":"2015","unstructured":"Zheng J, Woo S-L, Hu X, Botchlett R, Chen L, Huo Y, Wu C (2015) Metformin and metabolic diseases: a focus on hepatic aspects. Frontiers of medicine 9:173\u2013186","journal-title":"Frontiers of medicine"},{"key":"2551_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1211\/0022357001774732","volume":"52","author":"C-H Chou","year":"2000","unstructured":"Chou C-H (2000) Uptake and dispersion of metformin in the isolated perfused rat liver. J Pharm Pharmacol 52:1011\u20131016","journal-title":"J Pharm Pharmacol"},{"key":"2551_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:810\u2013820","journal-title":"Hepatology"},{"key":"2551_CR23","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1111\/febs.15587","volume":"288","author":"N Berndt","year":"2021","unstructured":"Berndt N, Eckstein J, Heucke N, Wuensch T, Gajowski R, Stockmann M, Meierhofer D, Holzhutter HG (2021) Metabolic heterogeneity of human hepatocellular carcinoma: implications for personalized pharmacological treatment. FEBS J 288:2332\u20132346","journal-title":"FEBS J"},{"key":"2551_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41416-019-0659-3","volume":"122","author":"N Berndt","year":"2020","unstructured":"Berndt N, Egners A, Mastrobuoni G, Vvedenskaya O, Fragoulis A, Dugourd A, Bulik S, Pietzke M, Bielow C, van Gassel R, Damink SWO, Erdem M, Saez-Rodriguez J, Holzhutter HG, Kempa S, Cramer T (2020) Kinetic modelling of quantitative proteome data predicts metabolic reprogramming of liver cancer. Br J Cancer 122:233\u2013244","journal-title":"Br J Cancer"},{"key":"2551_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/hep.31274","volume":"73","author":"N Berndt","year":"2021","unstructured":"Berndt N, Kolbe E, Gajowski R, Eckstein J, Ott F, Meierhofer D, Holzhutter HG, Matz-Soja M (2021) Functional consequences of metabolic zonation in murine livers: insights for an old story. Hepatology 73:795\u2013810","journal-title":"Hepatology"},{"key":"2551_CR26","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","volume":"49","author":"RS Hundal","year":"2000","unstructured":"Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063\u20132069","journal-title":"Diabetes"},{"key":"2551_CR27","first-page":"4059","volume":"81","author":"K Cusi","year":"1996","unstructured":"Cusi K, Consoli A, Defronzo RA (1996) Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059\u20134067","journal-title":"J Clin Endocrinol Metab"},{"key":"2551_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJM199803263381303","volume":"338","author":"SE Inzucchi","year":"1998","unstructured":"Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867\u2013873","journal-title":"N Engl J Med"},{"issue":"1","key":"2551_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1572-0241.2005.00307.x","volume":"101","author":"T Nishida","year":"2006","unstructured":"Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N (2006) Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Off J Am College Gastroenterol 101(1):70\u20135","journal-title":"Off J Am College Gastroenterol"},{"key":"2551_CR30","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00125-006-0271-y","volume":"49","author":"M Heishi","year":"2006","unstructured":"Heishi M, Ichihara J, Teramoto R, Itakura Y, Hayashi K, Ishikawa H, Gomi H, Sakai J, Kanaoka M, Taiji M, Kimura T (2006) Global gene expression analysis in liver of obese diabetic db\/db mice treated with metformin. Diabetologia 49:1647\u20131655","journal-title":"Diabetologia"},{"key":"2551_CR31","doi-asserted-by":"publisher","first-page":"e1006005","DOI":"10.1371\/journal.pcbi.1006005","volume":"14","author":"N Berndt","year":"2018","unstructured":"Berndt N, Horger MS, Bulik S, Holzhutter HG (2018) A multiscale modelling approach to assess the impact of metabolic zonation and microperfusion on the hepatic carbohydrate metabolism. PLoS Comput Biol 14:e1006005","journal-title":"PLoS Comput Biol"},{"key":"2551_CR32","doi-asserted-by":"publisher","first-page":"e2211933120","DOI":"10.1073\/pnas.2211933120","volume":"120","author":"N Tobar","year":"2023","unstructured":"Tobar N, Rocha GZ, Santos A, Guadagnini D, Assalin HB, Camargo JA, Gon\u00e7alves AE, Pallis FR, Oliveira AG, Rocco SA (2023) Metformin acts in the gut and induces gut-liver crosstalk. Proc Natl Acad Sci 120:e2211933120","journal-title":"Proc Natl Acad Sci"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-025-02551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-025-02551-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-025-02551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:50:11Z","timestamp":1757173811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-025-02551-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2551"],"URL":"https:\/\/doi.org\/10.1007\/s00109-025-02551-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4717542\/v1","asserted-by":"object"}]},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol conformed to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Charit\u00e9-Universit\u00e4tsmedizin Berlin (EA2\/059\/14).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all parents or guardians. Patients were recruited from the pediatric obesity outpatient clinic and pediatric gastroenterology outpatient clinic of the Charit\u00e9.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Informedconsent"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}